Overexpression of Hippo pathway effector TAZ in tongue squamous cell carcinoma: Correlation with clinicopathological features and patients' prognosis

Journal of Oral Pathology and Medicine

Volumn 42, Issue 10, 2013, Pages 747-754

  Wei, Zicheng ^a   Wang, Yanling ^a   Li, Zhongwu ^a   Yuan, Chunping ^a   Zhang, Wei ^a   Wang, Dongmiao ^a   Ye, Jinhai ^a   Jiang, Hongbin ^a   Wu, Yunong ^a   Cheng, Jie ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Hippo signaling; Prognostic marker; TAZ; Tongue squamous cell carcinoma

Indexed keywords

PROTEIN; TRANSCRIPTIONAL COACTIVATOR WITH PDZ BINDING MOTIF PROTEIN; UNCLASSIFIED DRUG; KI 67 ANTIGEN; SIGNAL PEPTIDE; TUMOR MARKER; WWTR1 PROTEIN, HUMAN;

ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; EPITHELIUM CELL; FOLLOW UP; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; OVERALL SURVIVAL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TONGUE CARCINOMA; WESTERN BLOTTING; ADULT; AGED; CELL LINE; CHEMISTRY; CULTURE TECHNIQUE; CYTOLOGY; FEMALE; FORECASTING; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; MOUTH MUCOSA; PATHOLOGY; PROGNOSIS; SECONDARY; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TONGUE TUMOR; TREATMENT OUTCOME; TUMOR CELL LINE;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CELL CULTURE TECHNIQUES; CELL LINE; CELL LINE, TUMOR; DISEASE-FREE SURVIVAL; EPITHELIAL CELLS; FEMALE; FOLLOW-UP STUDIES; FORECASTING; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KI-67 ANTIGEN; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MOUTH MUCOSA; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; TONGUE NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84887223016     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/jop.12062     Document Type: Article

References (32)

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-917.
2. Argiris A, Karamouzis MV, Raben D, et al. Head and neck cancer. Lancet 2008; 37: 1695-709.
3. Scully C, Bagan JV. Recent advances in oral oncology 2008; squamous cell carcinoma imaging, treatment, prognostication and treatment outcomes. Oral Oncol 2009; 45: e25-30.
4. Bello IO, Soini Y, Salo T. Prognostic evaluation of oral tongue cancer: means, markers and perspectives (I). Oral Oncol 2010; 46: 630-5.
5. Bello IO, Soini Y, Salo T. Prognostic evaluation of oral tongue cancer: means, markers and perspectives (II). Oral Oncol 2010; 46: 636-43.
6. Pan D. The hippo signaling pathway in development and cancer. Dev Cell 2010; 19: 491-505.
7. Kanai F, Marignani PA, Sarbassova D, et al. TAZ: a novel transcriptional co-activator regulated by interactions with 14-3-3 and PDZ domain proteins. EMBO J 2000; 19: 6778-91.
8. Hong W, Guan KL. The YAP and TAZ transcription co-activators: key downstream effectors of the mammalian Hippo pathway. Semin Cell Dev Biol 2012; 23: 785-93.
9. Overholtzer M, Zhang J, Smolen GA, et al. Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci USA 2006; 103: 12405-10.
10. Zhang X, George J, Deb S, et al. The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene. Oncogene 2011; 30: 2810-22.
11. Muramatsu T, Imoto I, Matsui T, et al. YAP is a candidate oncogene for esophageal squamous cell carcinoma. Carcinogenesis 2011; 32: 389-98.
12. Zhang H, Liu CY, Zha ZY, et al. TEAD transcription factors mediate the function of TAZ in cell growth and epithelial-mesenchymal transition. J Biol Chem 2009; 284: 13355-62.
13. Varelas X, Sakuma R, Samavarchi-Tehrani P, et al. TAZ controls Smad nucleocytoplasmic shuttling and regulates human embryonic stem-cell self-renewal. Nat Cell Biol 2008; 10: 837-48.
14. Hong JH, Hwang ES, McManus MT, et al. TAZ, a transcriptional modulator of mesenchymal stem cell differentiation. Science 2005; 309: 1074-8.
15. Cui CB, Cooper LF, Yang X, Karsenty G, Aukhil I. Transcriptional coactivation of bone-specific transcription factor Cbfa1 by TAZ. Mol Cell Biol 2003; 23: 1004-13.
16. Chan SW, Lim CJ, Guo K, et al. A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. Cancer Res 2008; 68: 2592-8.
17. de Cristofaro T, di Palma T, Ferraro A, et al. TAZ/WWTR1 is overexpressed in papillary thyroid carcinoma. Eur J Cancer 2011; 47: 926-33.
18. Zhou Z, Hao Y, Liu N, Raptis L, Tsao MS, Yang X. TAZ is a novel oncogene in non-small cell lung cancer. Oncogene 2011; 30: 2181-6.
19. Bhat KP, Salazar KL, Balasubramaniyan V, et al. The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. Genes Dev 2011; 25: 2594-609.
20. Chan SW, Lim CJ, Loo LS, Chong YF, Huang C, Hong W. TEADs mediate nuclear retention of TAZ to promote oncogenic transformation. J Biol Chem 2009; 284: 14347-58.
21. Cordenonsi M, Zanconato F, Azzolin L, et al. The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell 2011; 147: 759-72.
22. Zhong LP, Pan HY, Zhou XJ, et al. Characteristics of a cancerous cell line, HIOEC-B(a)P-96, induced by benzo(a)pyrene from human immortalized oral epithelial cell line. Arch Oral Biol 2008; 53: 443-52.
23. Zhang L, Ye DX, Pan HY, et al. Yes-associated protein promotes cell proliferation by activating Fos Related Activator-1 in oral squamous cell carcinoma. Oral Oncol 2011; 47: 693-7.
24. Liu LK, Jiang XY, Zhou XX, Wang DM, Song XL, Jiang HB. Upregulation of vimentin and aberrant expression of E-cadherin/beta-catenin complex in oral squamous cell carcinomas: correlation with the clinicopathological features and patient outcome. Mod Pathol 2010; 23: 213-24.
25. Goldie SJ, Mulder KW, Tan DW, et al. FRMD4A upregulation in human squamous cell carcinoma promotes tumor growth and metastasis and is associated with poor prognosis. Cancer Res 2012; 72: 3424-36.
26. Harvey KF, Hariharan IK. The hippo pathway. Cold Spring Harb Perspect Biol 2012; 4: a011288.
27. Lei QY, Zhang H, Zhao B, et al. TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway. Mol Cell Biol 2008; 28: 2426-36.
28. Lamar JM, Stern P, Liu H, Schindler JW, Jiang ZG, Hynes RO. The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain. Proc Natl Acad Sci USA 2012; 109: E2441-50.
29. Xu MZ, Yao TJ, Lee NP, et al. Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer 2009; 115: 4576-85.
30. Hergovich A, Hemmings BA. TAZ-mediated crosstalk between Wnt and Hippo signaling. Dev Cell 2010; 18: 508-9.
31. Rapidis AD, Gullane P, Langdon JD, Lefebvre JL, Scully C, Shah JP. Major advances in the knowledge and understanding of the epidemiology, aetiopathogenesis, diagnosis, management and prognosis of oral cancer. Oral Oncol 2009; 45: 299-300.
32. Xie M, Zhang L, He CS, et al. Prognostic significance of TAZ expression in resected non-small cell lung cancer. J Thorac Oncol 2012; 7: 799-807.